Analyst Ratings For BioTelemetry Inc (NASDAQ:BEAT)
Today, Raymond James raised its price target on BioTelemetry Inc (NASDAQ:BEAT) to $66.00 per share.
There are 5 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.
The current consensus rating on BioTelemetry Inc (NASDAQ:BEAT) is Buy with a consensus target price of $63.60 per share, a potential 5.56% upside.
Some recent analyst ratings include
- 2/23/2018-BioTelemetry Inc (NASDAQ:BEAT) had its Buy ➝ Buy rating reiterated by Dougherty & Co with a $41.00 price target
- 9/15/2017-BioTelemetry Inc (NASDAQ:BEAT) has coverage initiated with a Sell rating
- 8/10/2017-BioTelemetry Inc (NASDAQ:BEAT) had its Buy rating reiterated by Sidoti with a $49.00 price target
Recent Insider Trading Activity For BioTelemetry Inc (NASDAQ:BEAT)
BioTelemetry Inc (NASDAQ:BEAT) has insider ownership of 9.60% and institutional ownership of 93.83%.
- On 8/31/2018 Daniel Wisniewski, SVP, sold 31,000 with an average share price of $60.45 per share and the total transaction amounting to $1,873,950.00.
- On 7/27/2018 Joseph H Capper, CEO, sold 300,000 with an average share price of $53.92 per share and the total transaction amounting to $16,176,000.00.
- On 7/23/2018 Kirk E Gorman, Director, sold 7,500 with an average share price of $50.74 per share and the total transaction amounting to $380,550.00.
- On 7/2/2018 Kirk E Gorman, Director, sold 7,500 with an average share price of $45.49 per share and the total transaction amounting to $341,175.00.
- On 6/13/2018 Joseph H Capper, CEO, sold 200,000 with an average share price of $43.86 per share and the total transaction amounting to $8,772,000.00.
- On 6/11/2018 Joseph H Capper, CEO, sold 54,921 with an average share price of $43.45 per share and the total transaction amounting to $2,386,317.45.
- On 5/31/2018 Rebecca W Rimel, Director, sold 9,338 with an average share price of $42.28 per share and the total transaction amounting to $394,810.64.
About BioTelemetry Inc (NASDAQ:BEAT)
BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.
Recent Trading Activity for BioTelemetry Inc (NASDAQ:BEAT)
Shares of BioTelemetry Inc closed the previous trading session at 60.25 up +1.50 2.55% with 60.35 shares trading hands.
